Medindia

X

SuperGen to Present at the Citi Investment Research Global Healthcare Conference on May 22, 2008

Thursday, May 15, 2008 General News J E 4
Advertisement
DUBLIN, Calif., May 15 SuperGen, Inc.(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapiddevelopment and commercialization of therapies for solid tumors andhematological malignancies, today announced that James S. Manuso, Ph.D.,President and Chief Executive Officer, is scheduled to present at the CitiInvestment Research Global Healthcare Conference on May 22, 2008 at the HiltonHotel in New York.

SuperGen's presentation at the Citi Investment Research Global HealthcareConference is scheduled to begin at 3:00 p.m. EDT (12:00 p.m. PDT). A livewebcast of the presentation will be available on the investor relationssection of the Company's Web site at www.supergen.com. A webcast replay ofthe presentation will be available for 90 days.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical companydedicated to the discovery, rapid development and commercialization oftherapies for solid tumors and hematological malignancies. SuperGen isdeveloping a number of therapeutic anticancer products focused on kinase andcell signaling inhibitors and DNA methyltransferase inhibitors. For moreinformation about SuperGen, please visit http://www.supergen.com.Contacts Timothy L. Enns SuperGen, Inc. SVP, Corporate Communications & Business Development Tel: (925) 560-0100 E-mail: tenns@supergen.com Mary M. Vegh SuperGen, Inc. Manager, Investor Relations Tel: (925) 560-2845 E-mail: mary.vegh@supergen.com

SOURCE SuperGen, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Response Biomedical Corporation Announces First Qu...
S
Novavax Completes Enrollment in Phase I/IIa Pandem...